Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Auteur principal: | Akter, Anika |
---|---|
Autres auteurs: | Alam, Marzia |
Format: | Thèse |
Langue: | English |
Publié: |
Brac University
2022
|
Sujets: | |
Accès en ligne: | http://hdl.handle.net/10361/17039 |
Documents similaires
-
Biologics and Biosimilars as Treatment Options for Psoriasis
par: Moya, Amena Khatun
Publié: (2023) -
Importance of biologics in rheumatoid arthritis management
par: Riyadh, S. M.
Publié: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
par: Afroza, Halima
Publié: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
par: Mehreen, Elnaj
Publié: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
par: Islam, Nahidul
Publié: (2023)